FASN and neoplasm: The administration of orlistat in representative high CSN6/FASN PDX dramatically inhibited the lipid droplets formation (BODIPY 493/503 staining) (Fig. 7g), increased caspase 3 cleavage (Fig. 7h), decreased Ki67 staining (Fig. 7h), and reduced tumor weight (Supplementary Fig. 6c), while orlistat’s impact on representative CSN6 low group is less impressive (Fig. 7g, h, Supplementary Fig. 6c).